Status:

NOT_YET_RECRUITING

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

Lead Sponsor:

Institut de cancérologie Strasbourg Europe

Conditions:

HER2-positive Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: According to previous results from PHARE study, a subgroup of patients with low-risk cancer (\< 3 cm) without axillary lymph node involvement or small (\< 2 cm) with minimal lymph node invo...

Detailed Description

PHARE-C is an open-label, randomized, phase III, non-inferiority trial, that will recruit patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer to allow for compar...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of the breast, nonmetastatic disease and non operated tumor
  • Without suspicious axillary nodes
  • Tumor size \< 30 mm
  • Eligibility to receive a weekly paclitaxel based chemotherapy for this cancer
  • Left Ventricular Ejection Fraction (LVEF) obtained and \> 50% as measured by echocardiography (Simpson method) or multigated acquisition scan (MUGA) at 3 months (-/+ 1 month)
  • Overexpression of HER-2 in the invasive component of the primary tumor as indicated by one of the following:
  • 3+ by immunohistochemistry (IHC) 2+ by IHC and confirmation by fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)
  • With signed Informed consent

Exclusion

  • Previous anti-HER2 treatment (except for HERCEPTIN)
  • Cardiac disease or other medical conditions preventing trastuzumab administration
  • Known allergy to trastuzumab, murine proteins or other excipients
  • Pregnant or breastfeeding women
  • Patients that are not able to comply to the protocol assessments for geographic, social or psychological reasons

Key Trial Info

Start Date :

December 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 15 2030

Estimated Enrollment :

800 Patients enrolled

Trial Details

Trial ID

NCT05388500

Start Date

December 15 2022

End Date

December 15 2030

Last Update

May 27 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.